Key result
Amlodipine/olmesartan (10/40 mg) and amlodipine/valsartan (10/320 mg) produced large placebo-corrected reductions in systolic (25.7 and 15.5 mmHg) and diastolic (15.9 and 9.8 mmHg) blood pressure.
Why the study?
Does amlodipine/olmesartan medoxomil or amlodipine/valsartan combination therapy reduce blood pressure more than monotherapy in patients with hypertension?
Does amlodipine/olmesartan medoxomil or amlodipine/valsartan combination therapy reduce blood pressure more than monotherapy in patients with hypertension?
Combination therapy with amlodipine and either olmesartan medoxomil or valsartan produces substantial and greater blood pressure reductions compared to monotherapy in hypertensive patients.
No takes yet. Share an insight, caveat, or question.
May inform combination choices in hypertension; leaves open confirmation versus monotherapy in randomized trials.
C. Venkata S. Ram (2008) conducted a review in hypertension. amlodipine/olmesartan medoxomil and amlodipine/valsartan vs. placebo and monotherapy was evaluated on change from baseline in least-squares mean seated diastolic BP and systolic BP. Amlodipine/olmesartan (10/40 mg) and amlodipine/valsartan (10/320 mg) produced large placebo-corrected reductions in systolic (25.7 and 15.5 mmHg) and diastolic (15.9 and 9.8 mmHg) blood pressure.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: